Live Quote · NASDAQPRDSHealthcare· Biotechnology

Pardes Biosciences, Inc.

$2.18 0.93%(+$0.02)
TickerSpark Score
62/100
Mixed
80
Valuation
30
Profitability
15
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRDS research report →

52-Week Range49% of range
Low
$0.75
Current
$2.18
High
$3.67
Company Overviewwww.pardesbio.com

About the company

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses.

CEO
Thomas G. Wiggans
IPO
2021
Employees
57
HQ
Carlsbad, CA, US

Price Chart

-34.94% · this period
$3.32$2.08$0.85Sep 08Mar 10Sep 08
Valuation
Market Cap
$135.19M
P/E
-1.35
P/S
0.00
P/B
0.70
EV/EBITDA
-0.81
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-41.86%
ROIC
-53.57%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-93,451,000 · -142.43%
EPS
$-1.61 · -136.76%
Op Income
$-99,817,000
FCF YoY
-94.96%
Performance & Tape
52W High
$3.67
52W Low
$0.75
50D MA
$2.03
200D MA
$1.70
Beta
0.42
Avg Volume
509.69K

Get TickerSpark's AI analysis on PRDS

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 31, 23Tananbaum James B.other1,000
Aug 31, 23Tananbaum James B.sell37,500
Aug 31, 23Tananbaum James B.sell75,000
Aug 31, 23Tananbaum James B.sell16,813,146
Aug 31, 23Tananbaum James B.sell37,500
Aug 31, 23WIGGANS THOMAS Gother50,000
Aug 31, 23WIGGANS THOMAS Gsell562,500
Aug 31, 23WIGGANS THOMAS Gsell985,000
Aug 31, 23WIGGANS THOMAS Gsell450,000
Aug 31, 23Varney Michael Davidsell37,500
Coverage · PRDS

Our PRDS coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on PRDS yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate PRDS report →
Internal Compare

Similar companies

Peers in the same neighborhood.